NCOA2

Across TCGA pan-cancer cohorts, NCOA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NCOA2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NCOA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NCOA2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, HNSC, and GBM are the cancer types where NCOA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.616	0.239	.003	23	view →
HNSC	OS	Quartile	All	0.814	0.970	.010	14	view →
GBM	OS	Median	All	0.463	0.294	.016	13	view →
LSCC	DFS	Tertile	III,IV	1.000	0.674	.019	9	view →
CCRCC	DFS	Tertile	IV	0.213	0.887	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NCOA2–LUAD (DFS)

Open the LUAD breakdown →